Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Poll|February 8, 2021
Poll: On the Realities of Legalizing Marijuana
Author(s)Psychiatric Times Editors
Key Takeaways
- Personalized treatment strategies are crucial in managing lung cancer brain metastases, enhancing patient outcomes.
- Targeted therapies and immunotherapies offer effective, less invasive alternatives to traditional treatments.
What are your thought about navigating these uncharted waters?
Advertisement
Do you believe legalizing marijuana is a good thing?
Advertisement
Related to this article
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5